No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer
- 118 Downloads
KeywordsAndrogen deprivation therapy Castration Metabolic syndrome Prostatic neoplasms
PBØ: Project development, Data management, Data analysis, Manuscript editing. TWK: Data management, Data analysis, Manuscript editing. MF: Project development, Data management, Data analysis, Manuscript writing.
Compliance with ethical standards
Conflict of interest
This is a letter to the editor not directly involving human participants or animals. The authors would like to declare the following conflicts of interest: Peter B. Østergren has received honorarium as a speaker for Astellas and Ferring. Mikkel Fode has received honorarium as a speaker and advisory board member for Astellas. Tobias Wirenfeldt Klausen has no conflicts of interest.
- 3.Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi: 10.1016/j.juro.2016.12.003 (Epub ahead of print) PubMedGoogle Scholar